Binocrit®

Binocrit®

ACTIVE PRINCIPLE:
epoetin alfa

INDICATION:
Anemia secondary to oncological processes
end-stage renal failure

DATE:
18/02/2008

STATUS:
Authorized

MORE INFORMATION

BioSim Newsletter

Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.

SUBSCRIBE